In breast cancer, targets such as MUC1 and CD70 are more consistently expressed than others that exhibit spatial heterogeneity, and dual-target strategies can mitigate this risk by pairing antigens with nonoverlapping escape mechanisms, such as oncogenes and structural proteins [7, 49]. The gene discussed is MUC1; the disease is breast cancer.